肝癌TACE治疗与术后保肝抗病毒治疗临床意义

目的 探讨肝细胞肝癌TACE治疗与术后保肝抗病毒治疗的临床意义.方法 70例肝细胞肝癌患者随机分为两组,对照组给予常规TACE治疗,治疗组在对照组基础上给予长期、持续保肝抗病毒治疗,比较两组HBV-DNA载量、复发与转移率、生存时间.结果 术后血清HBV-DNA载量对照组持续高水平,治疗组明显降低,术后2周两组血清HBV-DNA载量有显著差异性（P〈0.05） 对照组与治疗组术后复发与转移率分别为85.7%、35.9%,差异有统计学意义（P〈0.05） 治疗组较对照组可明显延长病人生存时间（P〈0.05）.结论 TACE联合保肝抗病毒治疗肝细胞肝癌可有效降低HBV-DNA载量与肿瘤复发与转移率,延长患者生存时间,具有较好的临床效果.

Clinical significance of liver-protecting and antiviral treatment on Hepatocellular carcinoma after TACE

Objective To investigate the clinical significance of TACE combined with liverprotect antiviral treatment on hepatocellular carcinoma. Methods：70 cases of hepatoceUular carcinoma who were late and middle Stages of Hcc and HBeAg masculine were divided into two groups in complete randomization： control group received routine TACE treatment, treatment group received TACE and liver -protecting antiviral treatment. The copies of HBV DNA, rate of recurrence and metastasis, survival time were analyzed respectively. Results Patients were followed up for 6 囗36 months after operations, the copies of HBV-DNA of control group after operations were high continuously, treatment group were significantly lower than those before the operation, the difference of copies of HBV-DNA two weeks after operations between the two group was significantly（P〈0.05）. The rate of recurrence and metastasis of control group and treatment group were 85.7% and 21.4%. There was significant difference between them （P〈0.05）. Survival time of treatment group was longer than that of control group significantly （P〈0.05）. Conclusion： TACE combined with postoperative liver-protecting and antiviral treatment on hepatocellular carcinoma which is late and middle Stages can reduce the copies of HBV-DNA, decrease tumor recurrence and metastasis rate, extend Survival time obviously. It＇s a safe and effective method.